Drug Profile

ALD 101

Alternative Names: ALD-101

Latest Information Update: 13 Apr 2016

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Aldagen
Class Stem cell therapies
Mechanism of Action Cell replacements

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

Yes - Metabolic disorders
New Molecular Entity No

Highest Development Phases

Discontinued Metabolic disorders

Most Recent Events

05 May 2014 Discontinued - Phase-III for Metabolic disorders in USA (IV)
08 Feb 2012 Aldagen has been acquired by Cytomedix
08 Dec 2009 Pharmacodynamics data from preclinical studies presented at the 51st Annual Meeting and Exposition of the American Society of Hematology (ASH-2009)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com